Platform
Proteins require a specific three-dimensional structure to function. Misfolded proteins can become toxic, leading to diseases known as proteinopathies.

ProMIS Neurosciences is a clinical-stage biotechnology company whose EpiSelect platform computationally predicts and validates conformational epitopes.
promisneurosciences.comCrawled Nov 21, 2026
Proteins require a specific three-dimensional structure to function. Misfolded proteins can become toxic, leading to diseases known as proteinopathies.
A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients With Early Alzheimer's Disease
ProMIS Neurosciences holds over 100 patents for disease-specific targets on misfolded proteins, including antibody and vaccine candidates for neurodegenerative diseases.
Bill Wyman advises corporate management teams in the pharmaceutical, finance, and technology industries. He has served on over twenty-five boards of public and private companies and co-founded Oliver Wyman & Company, a global management consulting firm.
ProMIS Neurosciences develops antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases. Its name reflects the company’s focus on protein misfolding.
ProMIS Neurosciences, Inc. (Nasdaq: PMN) researches antibody treatments for toxic misfolded proteins in Alzheimer’s, ALS, and Parkinson’s disease. The company operates offices in Toronto and Cambridge, Massachusetts.
The page describes ProMIS Neurosciences’ mission and team.
ProMIS Neurosciences has licensed Ossianix’s TXP1 technology, which enhances antibody delivery to the brain by over 65-fold in preclinical tests. The move aims to bolster the company’s PMN310 therapeutic franchise and broaden its development pipeline. This technology could improve targeting for neurodegenerative disease treatments.
ProMIS Neurosciences reports its third-quarter 2026 financial results, covering the period ending September 30. The clinical-stage biotech company develops antibody treatments for neurodegenerative diseases caused by toxic misfolded proteins. It also reaffirms its timeline for releasing first-quarter 2027 topline data from ongoing trials.
ProMIS Neurosciences names Ivana Rubino, Ph.D., Chief Commercial Officer. Rubino joins with over two decades of experience in Alzheimer’s disease clinical development and global medical strategy from Biogen and Roche. She will lead commercialization efforts for ProMIS’s neuroscience pipeline, leveraging her expertise in launch readiness and market access.
ProMIS Neurosciences reports second-quarter 2026 financial results and highlights progress in developing antibody therapeutics for neurodegenerative diseases caused by toxic misfolded proteins. The clinical-stage biotech company, listed on Nasdaq as PMN, continues advancing its pipeline targeting these protein-related disorders.
ProMIS Neurosciences reports no ARIA-E (amyloid-related imaging abnormalities-edema) observed in all genotypes, including APOE4 homozygotes, during a blinded six-month interim analysis of its PMN310 treatment in the PRECISE-AD Phase 1b Alzheimer’s disease trial. The company’s investigational therapy shows early safety signals in patients with varying genetic risk profiles. Biomarker data from the study remain under blinded review for further assessment.